2-hydroxyethyl 2-deoxy-3,5-bis-O-(2-hydroxyethyl)-6-O-{2-[(9E)-octadec-9-enoyloxy]ethyl}hexofuranoside

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-hydroxyethyl 2-deoxy-3,5-bis-O-(2-hydroxyethyl)-6-O-{2-[(9E)-octadec-9-enoyloxy]ethyl}hexofuranoside
• 英文别名: 2-[2-[3,5-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (E)-octadec-9-enoate
• 化学式: C₃₂H₆₀O₁₀
• 分子量: 604.8
• InChiKey: RGPBUVUVZKQNHD-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  42
• 可旋转键数：
  31
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• IMIDAZOLIUM ALKYL (METH)ACRYLATE POLYMERS
  申请人：Garcia Castro Ivette

  公开号：US20090060859A1

  公开（公告）日：2009-03-05

  The present invention relates to the use of imidazolium alkyl(meth)acrylate homo- and copolymers in cosmetic preparations and to the corresponding cosmetic preparations.

  本发明涉及在化妆品制剂中使用咪唑烷基（甲基）丙烯酸酯同聚物和共聚物，以及相应的化妆品制剂。
• [EN] MEANS AND METHODS FOR OCULAR DRUG DELIVERY<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'ADMINISTRATION DE MÉDICAMENT OCULAIRE
  申请人：UNIV GRONINGEN

  公开号：WO2015041520A1

  公开（公告）日：2015-03-26

  The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.

  该发明涉及利用聚合物纳米颗粒将治疗化合物传递给眼细胞或眼组织的组合物和方法。提供了一种药物载荷的胶束，包括自组装的两性生物聚合物，例如疏水修饰的核酸或多肽，用作眼科药物传递系统。还提供了用于预防或治疗眼科疾病的眼科组合物和方法。
• Method For the Production of a Keratin-Binding Effector Molecule
  申请人：Barg Heiko

  公开号：US20090098076A1

  公开（公告）日：2009-04-16

  The invention relates to a method of producing keratin-binding effector molecules, and to intermediates and end-products of the method according to the invention and to the use of the keratin-binding effector molecules produced according to the invention in dermocosmetics. In addition, the invention relates to a method of applying dermocosmetically active ingredients to skin and/or hair and to a method of increasing the residence time of an active ingredient on skin and hair.

  本发明涉及一种生产角蛋白结合效应分子的方法，以及根据本发明方法的中间体和最终产品，以及根据本发明生产的角蛋白结合效应分子在皮肤护理化妆品中的使用。此外，本发明还涉及一种将皮肤和/或头发上的皮肤护理活性成分应用的方法，以及增加活性成分在皮肤和头发上停留时间的方法。
• Dermocosmetic Preparations
  申请人：Wunsch Thomas

  公开号：US20080220031A1

  公开（公告）日：2008-09-11

  The present invention relates to dermocosmetic compositions comprising a compound comprising the structural element of the formula I where the radical Z has the following meaning: H, C 1 -C 22 alkyl group, C 6 -C 10 -aryl group, C 1 -C 22 -alkoxy group or a C 6 -C 10 -O-aryl group substituted by a C 1 -C 22 -alkyl or C-C 22 -alkoxy group, and the radicals R 1 to R 6 , independently of one another, have the following meaning: H, C 1 -C 22 -alkyl group, C 6 -C 10 -aryl group, O, OH, C 1 -C 22 -alkoxy group or a C 6 -C 10 -O-aryl group substituted by a C 1 -C 22 -alkyl or C 1 -C 22 -alkoxy group, it being possible for R 5 and R 6 to be bridged in such a way that a five- to eight-membered ring is formed and, in the case of a five-membered ring, this ring may be part of an oligomer as a result of covalent bonds at positions 3 and 4. The invention furthermore relates to the use of said compounds in dermocosmetic formulations and the use of the dermocosmetics according to the invention for reducing skin or hair damage caused by free radicals. The invention furthermore relates to the use of the compounds according to the invention for increasing the stability of dermocosmetic formulations.

  本发明涉及一种皮肤化妆品组合物，包括一个化合物，该化合物包含公式I的结构元素，其中基团Z的含义如下：H，C1-C22烷基，C6-C10芳基，C1-C22烷氧基或C6-C10-O-芳基，该芳基被C1-C22烷基或C-C22烷氧基取代；基团R1至R6，彼此独立，其含义如下：H，C1-C22烷基，C6-C10芳基，O，OH，C1-C22烷氧基或C6-C10-O-芳基，该芳基被C1-C22烷基或C1-C22烷氧基取代。其中R5和R6可以被桥接，形成五至八元环，如果是五元环，则该环可能作为寡聚物的一部分，由于在3和4位置的共价键而成。此外，本发明还涉及使用该化合物在皮肤化妆品配方中的应用，以及本发明中的皮肤化妆品用于减少由自由基引起的皮肤或头发损伤的应用。本发明还涉及使用本发明中的化合物来增加皮肤化妆品配方的稳定性。
• [EN] ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER<br/>[FR] SOLUTION D'ISOXAZOLINE CONTENANT DE LA VITAMINE E POUR UNE UTILISATION AVEC DE L'EAU POTABLE DÉSINFECTÉE
  申请人：INTERVET INT BV

  公开号：WO2016207234A1

  公开（公告）日：2016-12-29

  For the prevention of parasite infestation of animals, an isoxazoline can be administered by drinking water route. However the inventors have found that when the drinking water is sanitized, for instance by using hypochlorite, the isoxazoline becomes degraded. Surprisingly, the isoxazoline can be protected from degradation by the use of a vitamin E. A pharmaceutical composition can now be prepared containing a concentrated solution of the isoxazoline in a solvent and co-solvent, with vitamin E. The composition can be diluted in drinking water, even when sanitized, to prepare medicated drinking water for animals. This way an anti-parasitic treatment can be mass-administered, leading to a highly effective reduction of the parasite infestation of an animal, and its surroundings.

  为了预防动物寄生虫感染，可以通过饮用水途径给予异噁唑啉。然而，发明者发现当饮用水被消毒，例如使用次氯酸盐时，异噁唑啉会被降解。令人惊讶的是，维生素E的使用可以保护异噁唑啉免受降解。现在可以制备一种含有异噁唑啉浓缩溶液和溶剂、共溶剂以及维生素E的药物组合物。即使经过消毒，该组合物也可以被稀释在饮用水中，以制备用于动物的药物饮用水。通过这种方式，可以进行抗寄生虫治疗的大规模给药，从而高效地减少动物及其周围环境中寄生虫的感染。